NCT02923778 2026-03-18
Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
14 trialsNCT04794127 2026-02-18
TRABEPIO
Mario Negri Institute for Pharmacological Research
Phase 2 Completed
NCT07169344 2026-01-28
PROSARC-1
Oslo University Hospital
Phase 2 Recruiting
NCT07173972 2026-01-28
PROSARC-2
Oslo University Hospital
Phase 2 Recruiting
NCT05496569 2025-11-21
TQB3616 Capsules in the Treatment of Dedifferentiated Liposarcoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Terminated
NCT05886634 2025-10-20
A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT04438824 2025-10-14
Palbociclib and INCMGA00012 in People With Advanced Liposarcoma
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT04668300 2025-10-09
DOSa
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04557449 2025-10-01
CDK4i
Pfizer
Phase 2 Active not recruiting
NCT03899805 2025-08-28
A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas
Dana-Farber Cancer Institute
Phase 2 Completed
NCT05580588 2025-06-13
Open-Label Study of the CDK4/6 Inhibitor SPH4336 in Subjects With Locally Advanced or Metastatic Liposarcomas
Shanghai Pharma Biotherapeutics USA Inc.
Phase 2 Terminated
NCT02846987 2025-06-05
Study of Abemaciclib in Dedifferentiated Liposarcoma
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT03719430 2025-04-29
APX005M and Doxorubicin in Advanced Sarcoma
Columbia University
Phase 2 Active not recruiting
NCT03114527 2025-04-04
Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS)
Fox Chase Cancer Center
Phase 2 Active not recruiting